289 related articles for article (PubMed ID: 26818468)
1. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience.
Nuki Y; Esaki M; Asano K; Maehata Y; Umeno J; Moriyama T; Nakamura S; Matsumoto T; Kitazono T
Scand J Gastroenterol; 2016; 51(6):700-5. PubMed ID: 26818468
[TBL] [Abstract][Full Text] [Related]
2. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis.
Yamagami H; Nishida Y; Nagami Y; Hosomi S; Yukawa T; Otani K; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
Rom J Intern Med; 2017 Sep; 55(3):151-157. PubMed ID: 28222041
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis.
Takeuchi K; Shimoyama T; Yamamoto T
Dig Dis; 2018; 36(2):106-112. PubMed ID: 29050007
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience.
Filippi J; Laharie D; Michiels C; Flamand M; Bouguen G; Nancey S; Presles E; Paul S; Schneider S; Hébuterne X; Roblin X
J Crohns Colitis; 2015 Mar; 9(3):252-8. PubMed ID: 25588386
[TBL] [Abstract][Full Text] [Related]
5. Short-Term and Long-Term Outcomes of Infliximab and Tacrolimus Treatment for Moderate to Severe Ulcerative Colitis: Retrospective Observational Study.
Otsuka T; Ooi M; Tobimatsu K; Wakahara C; Watanabe D; Adachi S; Yasutomi E; Yamairi H; Ku Y; Yoshida M; Hoshi N; Kodama Y
Kobe J Med Sci; 2018 Dec; 64(4):E140-E148. PubMed ID: 30728340
[TBL] [Abstract][Full Text] [Related]
6. Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis.
Liu YJ; Fan H; Zhen WW; Yu X; Chen JT; Wang CD
Medicine (Baltimore); 2018 Aug; 97(32):e11440. PubMed ID: 30095612
[TBL] [Abstract][Full Text] [Related]
7. Similar Short- and Long-term Colectomy Rates with Ciclosporin and Infliximab Treatment in Hospitalised Ulcerative Colitis Patients.
Duijvis NW; Ten Hove AS; Ponsioen CI; van den Brink GR; Buskens CJ; Bemelman WA; Te Velde AA; D'Haens GR; Löwenberg M
J Crohns Colitis; 2016 Jul; 10(7):821-7. PubMed ID: 26818660
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment.
Boschetti G; Nancey S; Moussata D; Stefanescu C; Roblin X; Chauvenet M; Stroeymeyt K; Bouhnik Y; Flourié B
Dig Liver Dis; 2014 Oct; 46(10):875-80. PubMed ID: 25023007
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study.
Yamamoto T; Shimoyama T; Umegae S; Matsumoto K
Aliment Pharmacol Ther; 2016 Mar; 43(6):705-16. PubMed ID: 26762838
[TBL] [Abstract][Full Text] [Related]
11. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
[TBL] [Abstract][Full Text] [Related]
12. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.
Tsukamoto H; Tanida S; Mizoshita T; Ozeki K; Ebi M; Shimura T; Mori Y; Kataoka H; Kamiya T; Joh T
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):714-8. PubMed ID: 23411870
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Tacrolimus and Infliximab in Hospitalized Patients With Ulcerative Colitis.
Takahashi T; Shiga H; Tarasawa K; Shimoyama Y; Naito T; Moroi R; Kuroha M; Kakuta Y; Fushimi K; Fujimori K; Kinouchi Y; Masamune A
Clin Transl Gastroenterol; 2024 Jan; 15(1):e00642. PubMed ID: 37753937
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
[TBL] [Abstract][Full Text] [Related]
15. Successful use of infliximab and tacrolimus combination therapy in a patient with ulcerative colitis refractory to infliximab dose intensification plus azathioprine.
Cortes X; Borrás-Blasco J; Fernendez S; Moreno M; Rodríguez J; Molés JR; Casterá E
Int J Clin Pharmacol Ther; 2016 Feb; 54(2):125-8. PubMed ID: 26754306
[TBL] [Abstract][Full Text] [Related]
16. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis.
Zhao HN; Jiang M; Sun MJ; Dai C
Saudi J Gastroenterol; 2021; 27(4):191-200. PubMed ID: 34380865
[TBL] [Abstract][Full Text] [Related]
18. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients.
Kitayama M; Akazawa Y; Yoshikawa D; Higashi S; Morisaki T; Oda H; Ikeda M; Nakashima Y; Tabuchi M; Hashiguchi K; Matsushima K; Yamaguchi N; Kondo H; Nakao K; Takeshima F
Sci Rep; 2020 Jul; 10(1):12546. PubMed ID: 32719413
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study.
Minami N; Yoshino T; Matsuura M; Koshikawa Y; Yamada S; Toyonaga T; Madian A; Honzawa Y; Nakase H
BMJ Open Gastroenterol; 2015; 2(1):e000021. PubMed ID: 26462273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
